Abstract:Background: Ciprofloxacin is usually used in the treatment of lower respiratory tract infections (LRTIs). Recent studies abroad have shown ciprofloxacin is inadequately dosed and might lead to worse outcomes. The aim of this study was to perform pharmacokinetic and pharmacodynamic analyses of ciprofloxacin in elderly Chinese patients with severe LRTIs caused by Gramnegative bacteria. Methods: From September 2012 to June 2014, as many as 33 patients were empirically administered beta-lactam and ciprofloxacin combination therapy. Patients were in fused with 200 or 400 mg of ciprofloxacin every 12 h, which was determined empirically by the attending physician based on the severity of the LRTI and the patient's renal condition. Ciprofloxacin serum concentrations were determined by high-performance liquid chromatography. Bacterial culture was performed from sputum samples and/or endotracheal aspirates, and the minimum inhibitory concentrations (MICs) of ciprofloxacin were determined. The ratios of the area under the serum concentration-time curve to the MIC (AUC/MIC) and of the maximum serum concentration of the drug to the MIC (C-max/MIC) were calculated. The baseline data and pharmacokinetic parameters were compared between clinical success group and clinical failure group, bacteriologic success group and bacteriologic failure group. Results: Among the 33 patients enrolled in the study, 17 were infected with Pseudomonas aeruginosa, 14 were infected with Acinetobacter baumannii, and two were infected with Klebsiella pneumoniae. The mean age of the patients was 76.9 +/- 6.7 years. Thirty-one patients (93.4%) did not reach the target AUC/MIC value of >125, and 29 patients (87.9%) did not reach the target C-max/MIC value of >8. The AUC/MIC and C-max/MIC ratios in the clinical success group were significantly higher than those in the clinical failure group (61.1 [31.7-214.9] vs. 10.4 [3.8-66.1], Z= -4.157; 9.6 [4.2-17.8] vs. 1.3 [0.4-4.7], Z= -4.018; both P< 0.001). The AUC/MIC and C-max/MIC ratios in the patients for whom the pathogens were eradicated were significantly higher than those in the patients without the pathogens eradicated (75.3 [31.7-214.9] vs. 10.5 [3.8-66.1], Z. 3.938; 11.4 [4.2-17.8] vs. 1.4 [0.4-5.4], Z.-3.793; P < 0.001 for both). Receiver operating characteristic curve analysis showed that the AUC/MIC and C-max/MIC values were closely associated with clinical and bacteriologic efficacies (P < 0.001 in both). Conclusions: Ciprofloxacin is inadequately dosed against Gram-negative bacteria, especially for those with relatively high MIC values. Consequently, the target values, AUC/MIC > 125 and C-max/MIC > 8, cannot be reached.

Pharmacokinetic study of cefazolin and ceftazidime in the elderly

Pharmacokinetic study of ofloxacin and ciprofloxacin in the elderly

Pharmacokinetics of cefpodoxime proxetil in healthy young and elderly volunteers

Analysis on the distribution and antibiotic resistance mechanism of healthy elderly intestinal Enterobacteriaceae bacteria

Pharmacokinetic-pharmacodynamic analysis of ciprofloxacin in elderly Chinese patients with lower respiratory tract infections caused by Gram-negative bacteria.

[Population Pharmacokinetics of Ciprofloxacin in Chinese Elderly Patients with Lower Respiratory Tract Infection].

A randomized controlled clinical study of aztraonam in treatment of 60 elderly patients with low respiratory tract bacterial infections

Study on Clinical Pharmacokinetics and Pharmacodynamics of Cefprozil

Curative Effect Analysis of Cefoxitin Sodium in the Treatment of Senile Bacterial Lower Respiratory Tract Infection

Pharmacokinetics of sulbactam/cefoperazone ( 1∶1 ) in healthy adult and old people

Population pharmacokinetic analysis of ciprofloxacin in the elderly patients with lower respiratory tract infections

[Comparison of Pharmacokinetics/pharmacodynamics of Cefdinir, Cefpodoxime Proxetil and Cefaclor Against Common Bacteria of Community Acquired Infections].

Comparative analysis on effective of cefoperazone and imipenem in treatment of G- bacteria infection in elderly patients

Population pharmacokinetics-pharmacodynamics of ceftazidime in neonates and young infants: Dosing optimization for neonatal sepsis

A randomized controlled study on cefpirome versus ceftazidime in the treatment of bacterial infections

Pharmacokinetics of Vancomycin in Elderly and Young Healthy Volunteers

Effects of food intake and age on the pharmacokinetics of AS-924, a novel ester-type cephem antibiotic. Comparison with cefpodoxime proxetil

Analysis of the Medication of Elderly Patients with Community-acquired Pneumonia in Our Hospital from 2010 to 2012

Levofloxacin-ceftazidime administration regimens combat Pseudomonas aeruginosa in the hollow-fiber infection model simulating abnormal renal function in critically ill patients

Study on the pharmacokinetics of Cefazolin and HPLC assay for the serum concentration

Study on clinical pharmacokinetics of cefpiramide